查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750790

美国生物样本库市场规模、份额、趋势分析报告：按产品/服务、生物检体、类型、应用、地区、细分预测，2025-2030 年

U.S. Biobanks Market Size, Share & Trends Analysis Report By Product & Service, By Biospecimen (Human Tissues, Organs, Stem Cells), By Type (Physical/Real Biobanks, Virtual Biobanks), By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

美国生物库市场的成长与趋势：

根据 Grand View Research, Inc. 的新报告，美国生物库市场规模预计到 2030 年将达到 244.8 亿美元，2025 年至 2030 年的复合年增长率为 6.26%。

这一增长源于药物开发、个人化医疗和临床研究对高品质生物检体的需求不断增长。生物银行技术的进步、製药和生物技术公司投资的增加以及基因组学和再生医学应用的不断扩展，进一步推动了市场扩张。

精准医疗日益受到重视，极大地推动了美国医疗保健和研究机构对高品质、带註释的生物检体的需求。这些样本对于支持生物标记发现、患者分层和标靶治疗开发等关键活动至关重要。生物样本库在此过程中发挥关键作用，它提供可靠的途径来获取多样化、临床相关的生物检体，这些样本对于转化研究和药物开发至关重要。随着製药公司、研究机构和诊断公司优先考虑个人化治疗方法，他们对生物样本库基础设施的依赖预计将显着增加。预计这一趋势将在预测期内推动持续的市场需求。

由于迫切需要生物检体来支持疫苗研发、诊断创新和公共卫生研究，COVID-19 疫情显着加速了美国对生物样本库的需求。生物样本库在收集、保存和分发 COVID-19 相关样本方面发挥了关键作用，使我们能够快速应对新出现的变异株，并增进我们对疾病进展的理解。生物样本库的贡献有助于加速临床试验，支持监管核准，并在疫情期间推动治疗和预防策略。

然而，美国市场受到有关资料隐私、知情同意和样本可追溯性的严格监管要求以及高昂的基础设施和维护成本的限制——这些挑战可能会限制可扩充性，尤其是对于较小的机构和新兴企业。

美国生物样本库市场报告重点

  • 预计服务领域将在2024年占据最大的市场占有率，并在预测期内以最快的复合年增长率增长，这得益于端到端样品管理、处理和存储解决方案的需求不断增长，尤其是在製药和研究领域。预计产品领域将在预测期内实现显着成长。
  • 人体组织领域预计将在2024年占据市场占有率达到36.91%，这得益于其在疾病研究、生物标记发现和药物开发（尤其是在肿瘤学和再生医学领域）中的关键作用。然而，预计干细胞的成长速度最快，预测期内复合年增长率将达到7.40%。
  • 预计到2024年，实体生物样本库将占据最大的市场占有率，这得益于其完善的基础设施、在受控条件下储存多样化生物检体的能力，以及在临床试验和转化研究中的广泛应用。然而，虚拟生物样本库预计在预测期内将以最快的复合年增长率成长。
  • 预计到2024年，治疗领域将在应用领域占据最大份额，并在预测期内实现最快的复合年增长率。这得归功于生物库样本在标靶治疗、再生疗法和个人化医疗方法开发中日益普及的现象。然而，临床诊断领域预计在预测期内也将显着成长。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国生物样本库市场分析工具
    • 产业分析—波特五力分析
    • PESTEL分析
    • COVID-19影响分析

第四章美国生物库市场：产品与服务估计与趋势分析

  • 产品/服务细分仪表板
  • 美国生物样本库市场产品与服务变化分析
  • 美国生物样本库市场规模及趋势分析（依产品/服务，2018-2030）
  • 产品
    • 2018-2030年产品市场
    • 生物银行设备
    • 生物银行耗材
    • 实验室资讯管理系统
  • 服务
    • 服务市场，2018-2030
    • 生物银行库
    • 实验室处理
    • 资格/检验
    • 低温运输物流
    • 其他服务

第五章美国生物样本库市场：生物检体估计与趋势分析

  • 生物检体细分仪表板
  • 美国生物样本库市场生物检体变异分析
  • 美国生物检体样本库市场规模与趋势分析（2018-2030年）
  • 人体组织
    • 人体组织市场，2018-2030
  • 器官
    • 器官市场，2018-2030
  • 干细胞
    • 干细胞市场，2018-2030
    • 成体干细胞
    • 胚胎干细胞
    • IPS细胞
    • 其他干细胞
  • 其他生物标本
    • 其他生物检体市场，2018-2030

第六章美国生物样本库市场：类型评估与趋势分析

  • 类型细分仪表板
  • 美国生物样本库市场波动分析
  • 美国生物样本库市场规模与趋势分析（2018-2030）
  • 物理/物理生物库
    • 实体生物样本库市场，2018-2030
    • 组织生物库
    • 基于人群的生物样本库
    • 遗传学（DNA/RNA）
    • 基于疾病的生物库
  • 虚拟生物库
    • 虚拟生物库市场，2018-2030

第七章：美国生物样本库市场：应用评估与趋势分析

  • 应用程式细分仪表板
  • 美国生物样本库市场使用趋势分析
  • 美国生物样本库市场规模及趋势分析（按应用，2018-2030）
  • 治疗
    • 治疗药物市场，2018-2030
  • 药物研发与临床研究
    • 2018-2030年药物研发与临床研究市场
  • 临床诊断
    • 临床诊断市场，2018-2030
  • 其他用途
    • 其他应用市场，2018-2030年

第八章 竞争态势

  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • QIAGEN
    • Hamilton Company
    • Tecan Trading Ag
    • ViaCord（Revitty）
    • Cryo-Cell
    • BioCision, Llc.
    • Icbiomedical
    • Charles River Laboratories
    • Azenta US Inc.
    • Stemcell Technologies
    • Biovault Family
    • LabVantage Solutions Inc.
    • Precision Cellular Storage Ltd.
Product Code: GVR-4-68040-585-1

U.S. Biobanks Market Growth & Trends:

The U.S. biobanks market size is anticipated to reach USD 24.48 billion by 2030 and is projected to grow at a CAGR of 6.26% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is attributed to rising demand for quality biospecimens in drug development, personalized medicine, and clinical research. Advancements in biobanking technologies, growing investments from pharmaceutical and biotech firms, and expanding applications in genomics and regenerative medicine further drive market expansion.

The increasing emphasis on precision medicine significantly boosts the demand for quality, well-annotated biospecimens across the U.S. healthcare and research landscape. These samples are essential for supporting critical activities such as biomarker discovery, patient stratification, and the development of targeted therapies. Biobanks play a pivotal role in this process by offering reliable access to diverse and clinically relevant biological materials, vital for translational research and drug development. As pharmaceutical companies, research institutions, and diagnostics firms prioritize personalized treatment approaches, the reliance on biobank infrastructure is expected to grow substantially. This trend is poised to drive sustained market demand over the forecast period.

The COVID-19 pandemic significantly accelerated the demand for biobanks in the U.S., driven by the urgent need for biological specimens to support vaccine development, diagnostic innovation, and public health research. Biobanks played a vital role in collecting, preserving, and distributing COVID-19-related samples, enabling faster response to emerging variants and enhancing understanding of disease progression. Their contribution helped accelerate clinical trials, support regulatory approvals, and advance therapeutic and preventive strategies during the pandemic.

However, the U.S. market faces constraints due to high infrastructure and maintenance costs, along with stringent regulatory requirements related to data privacy, informed consent, and sample traceability. These challenges can limit scalability, particularly for smaller institutions and emerging players.

U.S. Biobanks Market Report Highlights:

  • The services held the largest market share in 2024 and are anticipated to grow at the fastest CAGR over the forecast period. This is attributed to increasing demand for end-to-end sample management, processing, and storage solutions, especially from the pharma and research sectors. The product segment is expected to grow significantly over the forecast period.
  • The human tissues segment dominated with a market share of 36.91% in 2024. This is driven by their critical role in disease research, biomarker discovery, and drug development, particularly in oncology and regenerative medicine. However, stem cells are anticipated to grow at the fastest CAGR of 7.40% over the forecast period.
  • The physical/real biobank held the largest market share in 2024. This is driven by their established infrastructure, ability to store diverse biospecimens under controlled conditions, and widespread use in clinical trials and translational research. However, virtual biobank types are anticipated to grow at the fastest CAGR over the forecast period.
  • The therapeutics segment dominated the application segment with the largest share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period. This is driven by the increasing use of biobanked samples in developing targeted treatments, regenerative therapies, and personalized medicine approaches. However, clinical diagnostics are expected to grow significantly over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Products & Services Segment
    • 1.2.2. Biospecimen Segment
    • 1.2.3. Type Segment
    • 1.2.4. Application Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increased focus on precision medicine and genetic testing
      • 3.2.1.2. Changes in biobanking operations
      • 3.2.1.3. Increase in the number of clinical trials
      • 3.2.1.4. Growing biobanking industry and research collaborations
      • 3.2.1.5. Technology advancement and automation
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Challenges in sharing biobanking data & limited access to biospecimens
      • 3.2.2.2. Sustainability challenges for biobanks
      • 3.2.2.3. Challenges associated with biobanking specimen management
  • 3.3. U.S. Biobanks Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Biobanks Market: Products & Services, Trend Analysis

  • 4.1. Products & Services Segment Dashboard
  • 4.2. U.S. Biobanks Market Products & Services Movement Analysis
  • 4.3. U.S. Biobanks Market Size & Trend Analysis, by Products & Services, 2018 to 2030 (USD Million)
  • 4.4. Products
    • 4.4.1. Products Market, 2018 - 2030 (USD Million)
    • 4.4.2. Biobanking Equipment
      • 4.4.2.1. Biobanking Equipment Market, 2018 - 2030 (USD Million)
      • 4.4.2.2. Temperature Control Systems
        • 4.4.2.2.1. Temperature Control Systems Market, 2018 - 2030 (USD Million)
        • 4.4.2.2.2. Freezers & Refrigerators
          • 4.4.2.2.2.1. Freezers & Refrigerators Market, 2018 - 2030 (USD Million)
        • 4.4.2.2.3. Cryogenic Storage Systems
          • 4.4.2.2.3.1. Cryogenic Storage Systems Market, 2018 - 2030 (USD Million)
        • 4.4.2.2.4. Thawing Equipment
          • 4.4.2.2.4.1. Thawing Equipment Market, 2018 - 2030 (USD Million)
      • 4.4.2.3. Incubators & Centrifuges
        • 4.4.2.3.1. Incubators & Centrifuges Market, 2018 - 2030 (USD Million)
      • 4.4.2.4. Alarms & Monitoring Systems
        • 4.4.2.4.1. Alarms & Monitoring Systems Market, 2018 - 2030 (USD Million)
      • 4.4.2.5. Accessories & Other Equipment
        • 4.4.2.5.1. Accessories & Other Equipment Market, 2018 - 2030 (USD Million)
    • 4.4.3. Biobanking Consumables
      • 4.4.3.1. Biobanking Consumables Market, 2018 - 2030 (USD Million)
    • 4.4.4. Laboratory Information Management Systems
      • 4.4.4.1. Laboratory Information Management Systems Market, 2018 - 2030 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market, 2018 - 2030 (USD Million)
    • 4.5.2. Biobanking & Repository
      • 4.5.2.1. Biobanking & Repository Market, 2018 - 2030 (USD Million)
    • 4.5.3. Lab processing
      • 4.5.3.1. Lab processing Market, 2018 - 2030 (USD Million)
    • 4.5.4. Qualification/ Validation
      • 4.5.4.1. Qualification/ Validation Market, 2018 - 2030 (USD Million)
    • 4.5.5. Cold Chain Logistics
      • 4.5.5.1. Cold Chain Logistics Market, 2018 - 2030 (USD Million)
    • 4.5.6. Other Services
      • 4.5.6.1. Other Services Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Biobanks Market: Biospecimen Estimates & Trend Analysis

  • 5.1. Biospecimen Segment Dashboard
  • 5.2. U.S. Biobanks Market Biospecimen Movement Analysis
  • 5.3. U.S. Biobanks Market Size & Trend Analysis, by Biospecimen, 2018 to 2030 (USD Million)
  • 5.4. Human Tissues
    • 5.4.1. Human Tissues Market, 2018 - 2030 (USD Million)
  • 5.5. Organs
    • 5.5.1. Organs Market, 2018 - 2030 (USD Million)
  • 5.6. Stem Cells
    • 5.6.1. Stem Cells Market, 2018 - 2030 (USD Million)
    • 5.6.2. Adult Stem Cells
      • 5.6.2.1. Adult Stem Cells Market, 2018 - 2030 (USD Million)
    • 5.6.3. Embryonic Stem Cells
      • 5.6.3.1. Embryonic Stem Cells Market, 2018 - 2030 (USD Million)
    • 5.6.4. IPS Cells
      • 5.6.4.1. IPS Cells Market, 2018 - 2030 (USD Million)
    • 5.6.5. Other Stem Cells
      • 5.6.5.1. Other Stem Cells Market, 2018 - 2030 (USD Million)
  • 5.7. Other Biospecimens
    • 5.7.1. Other Biospecimens Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Biobanks Market: Type Estimates & Trend Analysis

  • 6.1. Type Segment Dashboard
  • 6.2. U.S. Biobanks Market Type Movement Analysis
  • 6.3. U.S. Biobanks Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 6.4. Physical/Real Biobanks
    • 6.4.1. Physical/Real Biobanks Market, 2018 - 2030 (USD Million)
    • 6.4.2. Tissue Biobanks
      • 6.4.2.1. Tissue Biobanks Market, 2018 - 2030 (USD Million)
    • 6.4.3. Population Based Biobanks
      • 6.4.3.1. Population Based Biobanks Market, 2018 - 2030 (USD Million)
    • 6.4.4. Genetic (DNA/RNA)
      • 6.4.4.1. Genetic (DNA/RNA) Market, 2018 - 2030 (USD Million)
    • 6.4.5. Disease Based Biobanks
      • 6.4.5.1. Disease Based Biobanks Market, 2018 - 2030 (USD Million)
  • 6.5. Virtual Biobanks
    • 6.5.1. Virtual Biobanks Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Biobanks Market: Application Estimates & Trend Analysis

  • 7.1. Application Segment Dashboard
  • 7.2. U.S. Biobanks Market Application Movement Analysis
  • 7.3. U.S. Biobanks Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 7.4. Therapeutics
    • 7.4.1. Therapeutics Market, 2018 - 2030 (USD Million)
  • 7.5. Drug Discovery & Clinical Research
    • 7.5.1. Drug Discovery & Clinical Research Market, 2018 - 2030 (USD Million)
  • 7.6. Clinical Diagnostics
    • 7.6.1. Clinical Diagnostics Market, 2018 - 2030 (USD Million)
  • 7.7. Other Application
    • 7.7.1. Other Application Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Thermo Fisher Scientific, Inc.
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Merck KGaA
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. QIAGEN
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Hamilton Company
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Tecan Trading Ag
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. ViaCord (Revitty)
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Cryo-Cell
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. BioCision, Llc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Icbiomedical
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Charles River Laboratories
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. Azenta US Inc.
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Stemcell Technologies
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives
    • 8.3.13. Biovault Family
      • 8.3.13.1. Overview
      • 8.3.13.2. Financial Performance
      • 8.3.13.3. Product Benchmarking
      • 8.3.13.4. Strategic Initiatives
    • 8.3.14. LabVantage Solutions Inc.
      • 8.3.14.1. Overview
      • 8.3.14.2. Financial Performance
      • 8.3.14.3. Product Benchmarking
      • 8.3.14.4. Strategic Initiatives
    • 8.3.15. Precision Cellular Storage Ltd.
      • 8.3.15.1. Overview
      • 8.3.15.2. Financial Performance
      • 8.3.15.3. Product Benchmarking
      • 8.3.15.4. Strategic Initiatives

List of Tables

  • Table 1. U.S. biobanks market estimates & forecasts
  • Table 2. U.S. biobanks market estimates & forecasts, by products & services, 2018 - 2030 (USD Million)
  • Table 3. U.S. biobanks market estimates & forecasts, by biospecimen, 2018 - 2030 (USD Million)
  • Table 4. U.S. biobanks market estimates & forecasts, by type, 2018 - 2030 (USD Million)
  • Table 5. U.S. biobanks market estimates & forecasts, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market snapshot
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market trends & outlook
  • Fig. 7 Market segmentation & scope
  • Fig. 8 Market driver relevance analysis (Current & future impact)
  • Fig. 9 Market restraint relevance analysis (Current & future impact)
  • Fig. 10 PESTLE Analysis
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 Strategy framework
  • Fig. 13 Participant categorization
  • Fig. 14 U.S. biobanks market: Products & services outlook key takeaways
  • Fig. 15 U.S. biobanks market: Products & services movement analysis
  • Fig. 16 Products market, 2018 - 2030 (USD Million)
  • Fig. 17 Biobanking equipment market, 2018 - 2030 (USD Million)
  • Fig. 18 Temperature control systems market, 2018 - 2030 (USD Million)
  • Fig. 19 Freezers & refrigerators market, 2018 - 2030 (USD Million)
  • Fig. 20 Cryogenic storage systems market, 2018 - 2030 (USD Million)
  • Fig. 21 Thawing equipment market, 2018 - 2030 (USD Million)
  • Fig. 22 Incubators & centrifuges market, 2018 - 2030 (USD Million)
  • Fig. 23 Alarms & monitoring systems market, 2018 - 2030 (USD Million)
  • Fig. 24 Accessories & other equipment market, 2018 - 2030 (USD Million)
  • Fig. 25 Biobanking consumables market, 2018 - 2030 (USD Million)
  • Fig. 26 Laboratory information management systems market, 2018 - 2030 (USD Million)
  • Fig. 27 Services market, 2018 - 2030 (USD Million)
  • Fig. 28 Biobanking & repository market, 2018 - 2030 (USD Million)
  • Fig. 29 Lab processing market, 2018 - 2030 (USD Million)
  • Fig. 30 Qualification/validation market, 2018 - 2030 (USD Million)
  • Fig. 31 Cold chain logistics market, 2018 - 2030 (USD Million)
  • Fig. 32 Other services market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. biobanks market: Biospecimen outlook key takeaways
  • Fig. 34 U.S. biobanks market: Biospecimen movement analysis
  • Fig. 35 Human tissues market, 2018 - 2030 (USD Million)
  • Fig. 36 Organs market, 2018 - 2030 (USD Million)
  • Fig. 37 Stem cells tissues market, 2018 - 2030 (USD Million)
  • Fig. 38 Adult stem cells market, 2018 - 2030 (USD Million)
  • Fig. 39 Embryonic stem cells market, 2018 - 2030 (USD Million)
  • Fig. 40 IPS cells market, 2018 - 2030 (USD Million)
  • Fig. 41 Other stem cells market, 2018 - 2030 (USD Million)
  • Fig. 42 Other biospecimens market, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. biobanks market: Type outlook key takeaways
  • Fig. 44 U.S. biobanks market: Type movement analysis
  • Fig. 45 Physical/real biobanks market, 2018 - 2030 (USD Million)
  • Fig. 46 Tissue biobanks market, 2018 - 2030 (USD Million)
  • Fig. 47 Population-based biobanks market, 2018 - 2030 (USD Million)
  • Fig. 48 Genetic (DNA/RNA) market, 2018 - 2030 (USD Million)
  • Fig. 49 Disease-based biobanks market, 2018 - 2030 (USD Million)
  • Fig. 50 Virtual biobanks market, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. biobanks market: Application outlook key takeaways
  • Fig. 52 U.S. biobanks market: Application movement analysis
  • Fig. 53 Therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Drug discovery & clinical research market, 2018 - 2030 (USD Million)
  • Fig. 55 Clinical diagnostics market, 2018 - 2030 (USD Million)
  • Fig. 56 Other application market, 2018 - 2030 (USD Million)
  • Fig. 57 U.S. biobanks market, 2018 - 2030 (USD Million)
  • Fig. 58 Key companies profiled